Resistance to M2 inhibitors has also been identified for seasonal A/H1N1 influenza virus between seasons and countries. This variability has been associated with the co-circulation of 2 haemagglutinin (HA) A/H1N1 lineages; Subclade 2C (A/Hong Kong/2652/2006) was typically oseltamivir sensitive and carried S31N marker of amantadine resistance in M2 gene, whereas subclade 2B (A/Brisbane/59/2007) was amantadine sensitive and had oseltamivir resistant mutation H274Y (N2 numbering) in NA gene
7
. The Hong Kong data showed the emergence of dual resistant A/H1N1 viruses 7 .
With the persistence of amantadine-resistant viruses, use of the newer group of antiviral 'neuraminidase inhibitors' oseltamivir and zanamavir has been recommended for treatment and/or prevention of influenza A and B since 2007. Neuraminidase inhibitors block the release of progeny virions from a host cell by selectively binding to the active site of the neuraminidase enzyme. This inhibits cleavage of the sialyl-acid bond to the host receptor, thus the virus is unable to be released from infected host cells and spread to new cells. Mutations giving rise to NAI resistance are both influenza subtype and drug-specific. Various mutations at amino acid positions 118, 119, 151, 152, 222, 224, 227, 274, 276, 292, 294 , and a deletion at positions (∆)244-247 of NA gene of influenza A have been implicated towards resistance to oseltamivir and/ or zanamavir 8 
.
Resistance to NAIs among seasonal influenza virus was low (<0.1%) in the field isolates until 2006-2007 season. In late 2007 unexpected emergence and spread of oseltamivir resistance in seasonal A/H1N1, characterized by mutation H274Y of the NA gene was observed globally 9, 10 . The rise in resistance appeared to be due to the spontaneous emergence and transmission of H274Y mutant viruses rather than selection pressure due to increased oseltamivir use 10 . A similar mutation has also been shown to be associated with clinical failure of drug treatment in A/H5N1 zoonotic infections
11
. The A/H3N2 viruses remained sensitive to oseltamivir. 
Molecular detection of M2 and NA gene
RNA extraction and RT-PCR -Viral RNA was extracted from culture supernatant using the QIAamp Viral RNA Mini Kit (Qiagen, uSA). one step PCR [reverse transcription (RT)-PCR)] (Invitrogen Superscript III Platinum kit country) was performed to amplify M2 and NA gene for detection of established molecular markers using published and gene-specific primers [23] [24] [25] [26] and HA1 gene using CDC (unpublished) for phylogenetic analysis.
Sequencing -The amplicons for M2 (270 bp covering amino acid positions 26 to 31), N1 (253 bp covering 274 amino acid positions), N2 (1103 bp covering all known mutation sites from 118 to 294 amino acid position) and type B NA (1146bp covering all known mutation sites from 119 to 371 amino acid position) genes were purified using PCR purification kits (Qiagen). DNA sequencing was carried out using Big Dye terminator V 3.1 cycle sequencing ready reaction kit (ABI, foster City, CA, uSA) and unincorporated labelled ddNTPs (dideoxy nucleotides) were removed using Dye-X removal column purification kit (Qiagen). The sequencing was done on ABI 3730 DNA analyzer (ABI, foster City, CA, uSA) and pair wise sequence alignment and protein translation was performed with MEGA 4 program 27 . 
Drug susceptibility markers: M2

Results
Amantadine susceptibility of influenza A viruses
Seasonal A (H3N2) viruses -As summarized in Table I 
Neuraminidase drug susceptibility markers of influenza A and B viruses
A/H1N1 viruses -NA gene sequencing of 206 A/H1N1 isolates was done to assess oseltamivir resistance mutation H274Y (Table II) . up to November 2008 all A/H1N1 isolates were sensitive to oseltamivir while in December 2008 resistant seasonal A/H1N1 viruses were observed from Chennai. In 2009, resistant viruses were detected from Delhi (13/14), Kolkata (7/7), Chennai (5/5), Pune (10/12) and similar findings were reported from Kolkata. No other substitutions conferring resistance to oseltamivir were found in these isolates.
A/H3N2 viruses -A total of 272 A/H3N2 isolates were studied for the presence of substitutions at positions R118K, E119Q, D151E, R152K, I222V, R224K, E227D, H274Y, E276D, R292K, N294S and a ∆ 244-247, and none of the isolates had any of the reported oseltamivir-resistance conferring mutations. (Accession Nos: Kf 314400-Kf314591; Kf 314609-Kf314682; Kf014004,6,8,10) (Table II 
Amino acid sites were checked as follows: H3N2:R118K, E119Q, D151E, R152K, I222V, R224K, E227D, H274Y, E276D, R292K, N294S and a ∆ 244-247 , Type B: E119A, R152K, D198N/E, I222T, H274Y and R371K, H1N1 and P(H1N1): H274Y Type B viruses -A total of 326 type B isolates were sequenced for NA gene and lack of changes at positions E119A, R152K, D198N/E, I222T, H274Y and R371K indicated that all type B isolates were sensitive to oseltamivir (Accession Nos: Kf314197-Kf314399; Kf364360-Kf364482) (Table II) .
Pandemic (H1N1) viruses -Pandemic (H1N1) isolates (n=493) were screened for H274Y mutation in NA gene by allelic discrimination and all were sensitive to oseltamivir
Discussion
The acquisition of a mutation in influenza A viruses conferring resistance to an antiviral agent may occur as a result of drug selection, spontaneous mutation or through genetic reassortment with another drug resistant influenza A virus. High prevalence of amantadine resistance in influenza A viruses was observed in countries, irrespective of its use 5, 6 . Globally, a marked increase in amantadine drug resistant virus isolates was reported from Asian countries especially for A/H3N2 subtype 4 . In 2009, a single isolate from Kolkata had less common mutation L26f in M2 gene and H274Y mutation in NA gene which conferred dual resistance. Indian isolates with S31N mutation indicated that strains already harbouring drug resistant mutation were most likely introduced in the community. Since in India the use of amantadine for influenza treatment was extremely rare during the study period; the possibility of emergence of amantadine resistance due to drug pressure is remote.
Before 2008, oseltamivir-resistance for any influenza type/subtype was not observed in India, due to negligible use of oseltamivir till May 2009. Widespread use of oseltamivir for suspected H1N1 patients in India started after June 2009 when cases of pandemic A (H1N1) 09 were detected in India. Prior to this, use of antivirals for influenza was negligible indicating that there was no potential for drug resistance due to selective pressure. However, no evidence was found to suggest that increased access to oseltamivir had promoted resistance or lack of it. A similar study from Japan, where oseltamivir is more widely used, reported no significant effect on the occurrence of resistance
.
In India, a probable importation or detection of global 2008 oseltamivir-resistant seasonal A/H1N1 virus was documented nine months after it was first reported in Europe in January 2008 9, 10 . oseltamivir . Like influenza A viruses, influenza B viruses also undergo continuous evolution with accumulation of point mutations and reassortment events between cocirculating lineages. It was observed worldwide that the community acquired isolates of influenza B virus remained sensitive to NAI drugs. However, sporadic cases of reduced NAI susceptibility in the NA inhibition assays have been reported from drug treated patients 13 . our results showed that the influenza B viruses were sensitive to oseltamivir with agreement to global data.
Continued surveillance for antiviral drug resistance in influenza viruses is required to ensure that stockpiled neuraminidase inhibitors are effective and clinicians can be kept informed of the efficacy of neuraminidase inhibitors when treating patients for influenza.
